miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
复制标题
miR-638是一种新的生物标志物，用于预测接受化疗的非小细胞肺癌患者的预后。
DOI：
10.1038/emm.2015.17
复制
发表时间：
2015-05-08
影响因子：
12.8
通讯作者：
Wang, Hong
中科院分区：
文献类型：
--
作者：
Wang, Fang;Lou, Jian-fang;Cao, Yan;Shi, Xin-hui;Wang, Peng;Xu, Jian;Xie, Er-fu;Xu, Ting;Sun, Rui-hong;Rao, Jian-yu;Huang, Pu-wen;Pan, Shi-yang;Wang, Hong
microRNA（miRNAs）是一类小的非编码RNA，通过切割靶mRNA或抑制其翻译来介导基因表达。它们在包括非小细胞肺癌（NSCLC）在内的几种癌症的肿瘤发生中起关键作用。本研究的目的是探讨miR-638在评估NSCLC患者化疗预后中的临床意义。首先，我们检测了顺铂处理的NSCLC细胞系SPC-A1培养上清中miR-638的表达水平，以及SPC-A1的凋亡率。第二，通过使用携带SPC-A1的裸鼠异种移植模型在顺铂治疗和不治疗的情况下检测血清miR-638表达水平。在临床上，采用实时荧光定量PCR法检测200例NSCLC患者化疗前后血清miR-638水平，分析化疗后miR-638表达模式与临床病理特征的关系。我们的数据有助于证明顺铂以剂量和时间依赖性方式诱导SPC-A1细胞凋亡，并伴随培养上清液中miR-638表达水平的增加。体内数据进一步揭示，顺铂诱导源自小鼠异种移植模型的血清中的miR-638上调，并且在NSCLC患者血清中，化疗后miR-638表达模式与淋巴结转移显著相关。此外，生存分析显示，化疗后miR-638水平升高的患者的生存时间明显长于miR-638水平降低的患者。我们的研究结果表明，血清miR-638水平与NSCLC患者的生存相关，并可能被认为是NSCLC预后的潜在独立预测因子。
MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC). The aim of this study was to investigate the clinical significance of miR-638 in the evaluation of NSCLC patient prognosis in response to chemotherapy. First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. Second, serum miR-638 expression levels were detected in vivo by using nude mice xenograft models bearing SPC-A1 with and without cisplatin treatment. In the clinic, the serum miR-638 levels of 200 cases of NSCLC patients before and after chemotherapy were determined by quantitative real-time PCR, and the associations of clinicopathological features with miR-638 expression patterns after chemotherapy were analyzed. Our data helped in demonstrating that cisplatin induced apoptosis of the SPC-A1 cells in a dose- and time-dependent manner accompanied by increased miR-638 expression levels in the culture supernatants. In vivo data further revealed that cisplatin induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638 expression patterns after chemotherapy significantly correlated with lymph node metastasis. Moreover, survival analyses revealed that patients who had increased miR-638 levels after chemotherapy showed significantly longer survival time than those who had decreased miR-638 levels. Our findings suggest that serum miR-638 levels are associated with the survival of NSCLC patients and may be considered a potential independent predictor for NSCLC prognosis.
登录
查看更多内容
影响因子：
56.9
作者：
Thai, To-Ha;Calado, Dinis Pedro;Rajewsky, Klaus
通讯作者：
Rajewsky, Klaus
MicroRNA-638 在人血管平滑肌细胞中高表达，通过靶向孤儿核受体 NOR1 抑制 PDGF-BB 诱导的细胞增殖和迁移
影响因子：
10.8
作者：
Li, Pan;Liu, Yan;Sun, Jianxin
通讯作者：
Sun, Jianxin
影响因子：
3.7
作者：
Hotta K;Kiura K;Fujiwara Y;Takigawa N;Hisamoto A;Ichihara E;Tabata M;Tanimoto M
通讯作者：
Tanimoto M
影响因子：
1.6
作者：
Hong, Fanzhen;Li, Yuyang;Zhu, Lin
通讯作者：
Zhu, Lin
影响因子：
--
作者：
Liu, Guang-Hui;Zhou, Zong-Guang;Sun, Xiao-Feng
通讯作者：
Sun, Xiao-Feng